Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,324.80
(
-0.80%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
100.78
(
2.03%
)
Bitcoin
69,646.23
(
-2.32%
)
News Focus
News Focus
Post# of 257288
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 160992

Friday, 12/06/2013 2:24:42 PM

Friday, December 06, 2013 2:24:42 PM

Post# of 257288
GSK/THRX “son of Advair” phase-3 succeeds in asthma:

http://finance.yahoo.com/news/gsk-theravance-announce-positive-results-130000596.html

The combination ICS/LABA drug, called Breo Ellipta in the US, was approved for COPD in May 2013 (#msg-87790274). In many other countries, where the brand name is Relvar Ellipta, this comabination is approved for COPD and asthma.

Breo Ellipta should not be confused with Anoro Ellipta, GSK/THRX’s LABA/LAMA combination drug, where FDA approval is pending (#msg-91874192).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today